Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Dyslipidemia is associated with a prothrombotic phenotype; however, the mechanisms responsible for enhanced platelet reactivity remain unclear. Proatherosclerotic lipid abnormalities are associated with both enhanced oxidant stress and the generation of biologically active oxidized lipids, including potential ligands for the scavenger receptor CD36, a major platelet glycoprotein. Using multiple mouse in vivo thrombosis models, we now demonstrate that genetic deletion of Cd36 protects mice from hyperlipidemia-associated enhanced platelet reactivity and the accompanying prothrombotic phenotype. Structurally defined oxidized choline glycerophospholipids that serve as high-affinity ligands for CD36 were at markedly increased levels in the plasma of hyperlipidemic mice and in the plasma of humans with low HDL levels, were able to bind platelets via CD36 and, at pathophysiological levels, promoted platelet activation via CD36. Thus, interactions of platelet CD36 with specific endogenous oxidized lipids play a crucial role in the well-known clinical associations between dyslipidemia, oxidant stress and a prothrombotic phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Platelet hyperreactivity and thrombosis risk are enhanced in the setting of numerous conditions associated with atherosclerotic heart disease, such as hyperlipidemia, oxidant stress, and hyperglycemia (Podrez et al., 2007; Chen et al., 2008; Zhu et al., 2012a).”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Podrez et al., 2007
Citations
Cites
Antiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394 · cited 1×
“Because anti-inflammatory and antioxidant effects of HDL are well documente”
BackgroundFebbraio, M., Hajjar, D. P., & Silverstein, R. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14006 · Cited by 1,193 · cited 1×
“CD36 is implicated in a variety of pathological conditions, including atherosclerosis, diabetes and innate immunit”
BackgroundSelf-citationFebbraio, M., Podrez, E. A., Smith, J. D., Hajjar, D. P., Hazen, S. L., Hoff, H. F., Sharma, K., & Silverstein, R. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9259 · Cited by 1,044 · cited 1×
“Absence of CD36 in a mouse model of atherogenesis results in significant inhibition of atherosclerosi”
BackgroundSelf-citationCirculating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E
Huo, Y., Schober, A., Forlow, S. B., Smith, D. F., Hyman, M. C., Jung, S., Littman, D. R., Weber, C., & Ley, K. (2003) · Nature Medicine · doi:10.1038/nm810 · Cited by 1,005 · cited 1×
“Platelet P-selectin mediates the formation of platelet-monocyte aggregates, which have been implicated in several vascular disease processe”
BackgroundCD36 is a sensor of diacylglycerides
Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S., Shamel, L., Hartung, T., Zähringer, U., et al. (2005) · Nature · doi:10.1038/nature03253 · Cited by 873 · cited 1×
“To address any potential issues related to the mixed genetic background of the Cd36 −/− and Apoe −/− Cd36 −/− mice, we used independently generated, CD36-deficient 'oblivious' mic”
MethodWatson, A. D., Leitinger, N., Navab, M., Faull, K. F., Hörkkö, S., Witztum, J. L., Palinski, W., Schwenke, D., Salomon, R. G., Sha, W., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13597 · Cited by 753
Self-citationCD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism
André, P., Prasad, K. S. S., Denis, C. V., He, M., Papalia, J. M., Hynes, R. O., Phillips, D. R., & Wagner, D. D. (2002) · Nature Medicine · doi:10.1038/nm0302-247 · Cited by 726
Platelet Function in Hyperlipoproteinemia
Carvalho, A. C. A., Colman, R. W., & Lees, R. S. (1974) · New England Journal of Medicine · doi:10.1056/nejm197402212900805 · Cited by 679
Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infarction
Trip, M. D., Cats, V. M., van Capelle, F. J. L., & Vreeken, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222201 · Cited by 617
Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro
Podrez, E. A., Schmitt, D., Hoff, H. F., & Hazen, S. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5549 · Cited by 492
Self-citation
Cited by
Items 401–500 of 513
Hitsumoto, T. (2019) · Cardiology Research · doi:10.14740/cr858 · Cited by 4
“In addition, several studies have reported that oxidative stress could cause impairment of blood rheology [26, 27].”
BackgroundAre Patients Getting Their Aspirin's Worth in Ischemic Stroke?
Schmaier, A. A., & Bhatt, D. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009564 · Cited by 4
“Oxidized low-density lipoprotein and its metabolites can sensitize platelets to activate at a lower threshold.(9) Notably, diabetes mellitus was not associated with HAPR in this cohort, as has been demonstrated in other studies.”
ResultDib, P. R. B., FERNANDES, M. K. C., Venerando, L. A. F., Mancini, M. C., Januzzi, L. L. R., Lima, M. J. T., de Souza, V. P., REZENDE, C. P. D., Vieira, E. C. C., de Lima, M. F. C., et al. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.02.002 · Cited by 4
Bartoszewicz, M., & Rać, M. E. (2023) · Biomedicines · doi:10.3390/biomedicines11051332 · Cited by 4
“It has been observed that there is an essential link between oxidative lipid stress, CD36, and platelet hyperactivity, which leads to a prothrombotic phenotype with the deletion of CD36 [6].”
BackgroundNAFLD and AATD Are Two Diseases with Unbalanced Lipid Metabolism: Similarities and Differences
Pérez-Luz, S., Matamala, N., Gómez‐Mariano, G., Janciauskiene, S. M., & Martínez–Delgado, B. (2023) · Biomedicines · doi:10.3390/biomedicines11071961 · Cited by 3
Chronic diseases alter the platelet rheostat to promote hyperreactivity and thrombosis
Silverstein, R. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194082 · Cited by 3
“Our research has shown that the platelet scavenger receptor CD36, which recognizes oxLDL (2), AGE proteins (3), and microvesicles (4), increased the sensitivity of platelets to classical agonists and promoted arterial thrombosis in mouse models of diabetes, hyperlipidemia, and chronic systemic…”
Self-citationClinical Impact of Hemorheology on Subclinical Myocardial Injury in Patients with Hypertension
Hitsumoto, T. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3652 · Cited by 3
“In addition, several mechanisms are also reported by which oxidative stress causes impairment of hemorheology, such as platelet aggregation and elevation of plasma viscosity [43, 44].”
BackgroundAssociation of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
Wang, W., Luo, R., Pei, D. A., Huang, Q., Jin, X., Wu, Y., Xie, M., Wang, S., Sui, X.-Q., & Shen, B. (2023) · Medicine · doi:10.1097/md.0000000000033026 · Cited by 3
“LOX-1, CD36), facilitates platelet activation via binding to platelet surface.[39] Interestingly, PCSK9 increased the expression of LOX-1 and ox-LDL uptake in macrophages in an inflammatory milieu.”
BackgroundChyrchel, B., Kruszelnicka, O., Wieczorek‐Surdacka, E., & Surdacki, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134530 · Cited by 3
“First, the binding of oxidized lipids by the platelet CD36 receptor, a scavenger receptor implicated in atherogenesis and foam cell formation, is a recognized pathway linking dyslipidemia with excessive platelet activation [43,44].”
BackgroundDutta, P., Saha, D., Giri, A., Bhatnagar, A. R., & Chakraborty, A. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5030026 · Cited by 3
Fisiopatología del estado protrombótico en el síndrome metabólico
González, I. P., Moore‐Carrasco, R., Marcelo Alarcón, L., Rojas, A., Escudero, V., & Sandra Hasbún, A. (2009) · Acta Médica Colombiana · Cited by 8
Platelets and their Role in Thrombotic and Cardiovascular Disease: The Impact of Proteomic Analysis
Stanley, R. G., Tucker, K. L., Barrett, N. E., & Gibbins, J. M. (2011) · Wiley eBooks · doi:10.1002/9780470940297.ch1 · Cited by 4
Hemostatic abnormalities in diabetes mellitus
Ajjan, R., & Grant, P. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch72 · Cited by 3
The Vascular Function of Platelets
Watson, S. P., & Harrison, P. (2010) · doi:10.1002/9781444323160.ch40 · Cited by 3
Kindlin-3 phosphorylation is crucial for thrombosis and hemostasis in vivo
Pluskota, E., Szpak, D., Wang, Y., Qin, J., Simon, D. I., Plow, E. F., & Białkowska, K. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102863 · Cited by 3
“Bleeding time assays were performed as previously described [24].”
Moore, A. I., Moreira, A. S. P., Conde, T., Melo, T., Domingues, P. M., O’Boyle, N. M., & Domingues, M. R. (2025) · Contact Dermatitis · doi:10.1111/cod.14804 · Cited by 4
“Also, oxPLs have been shown to act as high-affinity ligands for macrophage scavenger receptor CD36, causing enhanced platelet activity, a contributing factor to dyslipidaemia [20].”
Lin, Y., Hsieh, T., Yeh, C., Yadav, V. K., Fong, I.-H., Kuo, K.-T., Kounis, N. G., Hu, P., & Hung, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091384 · Cited by 2
“Under chronic inflammation, oxidant stress, hyperlipidemia, or diabetes, CD36 deficiency alleviates atherosclerosis and thrombosis to maintain homeostasis [35].”
Platelet mitochondria dysfunction in diabetes mellitus: mechanisms and therapeutic implications
Yadava, S., Dontiboina, H. R., Dugluri, S., Yadagiri, G., Choudhury, P., & Kakarla, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1774791 · Cited by 2
Liu, Y., Li, J., Hu, L., Zhu, J., An, Q., & Guo, Y. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1785666 · Cited by 3
“Experimental evidence further demonstrates that oxLDL enhances platelet activation through CD36-dependent pathways and promotes platelet–leukocyte aggregate formation, thereby linking metabolic dysregulation to thrombo-inflammatory amplification (Flowers et al., 2025; Podrez et al., 2007).”
Fu, X., Brun, A., Dittrich, K., Cebo, M., Lackner, M., Menig-Benzig, L.-S., Bouzabia, B., Rheinlaender, J., Banks, H., von Eysmondt, H., et al. (2026) · Blood · doi:10.1182/blood.2025030939 · Cited by 2
Kaplan, Z., & Jackson, S. P. (2010) · Blood · doi:10.1182/blood-2010-06-289827 · Cited by 2
Xiong, T., Qian, A. S., & Trigatti, B. L. (2021) · Vessel Plus · doi:10.20517/2574-1209.2020.71 · Cited by 2
“CD36 on platelets can bind to Ox-LDL, which has been shown to promote platelet activation([103-105]).”
BackgroundAoyagi, R., Yamamoto, T. S., Furukawa, Y., & Arita, M. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00274 · Cited by 2
What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?
Tsimikas, S. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e7 · Cited by 2
Gatina, K. I. (2014) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2014/10630 · Cited by 2
“As cardiovascular pathology is associated with dyslipidemia and oxidative stress, one of the possible mechanisms that increase the risk of thrombotic complications is oxidation of choline glycerophospholipids that promote platelet activation and hyper reactivity [6,7].”
BackgroundTeaching an old dog new tricks: potential antiatherothrombotic use for statins
Silverstein, R. L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61857 · Cited by 2
Self-citationMesaros, C., Gugiu, B. G., Zhou, R., Lee, S. H., Choi, J., Laird, J. M., Blair, I. A., & Salomon, R. G. (2010) · Chemical Research in Toxicology · doi:10.1021/tx9002484 · Cited by 2
Self-citationGenetic determinants of responsiveness to antiplatelet therapy
Kral, B. G., Lawal, L., & Becker, L. C. (2008) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-008-0084-2 · Cited by 2
Platelet VIII pack evades immune detection
Ragni, M. V. (2016) · Blood · doi:10.1182/blood-2016-01-689869 · Cited by 2
Poli, G., Leonarduzzi, G., Gargiulo, S., Gamba, P., Sottero, B., Mascia, C., & Biasi, F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.10.679 · Cited by 2
Wang, H., Yan, W., Gong, L., Song, N.-P., Wang, C., & Zhong, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1066228 · Cited by 3
“suggested that platelet CD36 could serve as a sensor of specific oxidized phospholipids generated during oxidative stress, inducing an activating signal, and may result in platelet activation by subthreshold concentrations of physiological agonists (8).”
BackgroundRole of CD 36 in immune‐mediated thrombocytopenia in Asian populations
Xu, X., & Santoso, S. (2018) · ISBT Science Series · doi:10.1111/voxs.12414 · Cited by 2
Neokleous, N., Stavroula, M., & Perifanis, V. (2022) · Journal of Family Medicine · doi:10.26420/jfammed.2022.1312 · Cited by 1
Karwatowska‐Prokopczuk, E., Lu, L., Yang, J. M., Witztum, J. L., & Tsimikas, S. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02818-6 · Cited by 1
“Furthermore, the consequences of Lp(a)/OxPL lowering, which can be associated with alterations in platelet function [17, 18], are not known.”
BackgroundSimplified synthesis of oxidized phospholipids on alkyl-amide scaffold
Oskolkova, O., Gesslbauer, B., & Bochkov, V. N. (2025) · MethodsX · doi:10.1016/j.mex.2025.103288 · Cited by 1
“Truncated OxPLs are toxic [ 5 ], pro-inflammatory [ 6 ], and pro-thrombogenic [ 7 ].”
Lämmerhofer, M., & Chatterjee, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-96340-7_23 · Cited by 1
Gao, D., Singh, K. D., Karnik, S. S., Byzova, T. V., & Podrez, E. A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07761 · Cited by 8
Self-citationEfferocytosis: Gateway for tissue resolution
Cho, S., & Ju, H. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261431219 · Cited by 1
Simplifying causal gene identification in GWAS loci
Schipper, M., Ulirsch, J. C., Posthuma, D., Ripke, S., & Heilbron, K. (2026) · PLoS Genetics · doi:10.1371/journal.pgen.1012079 · Cited by 7
Campello, E., Boccatonda, A., Napolitano, A., Simion, C., & Simioni, P. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04351-9 · Cited by 1
Miao, Z., Chen, C.-X., Wang, P., Zheng, S.-L., Jiang, J.-B., Hu, W.-J., Zhu, X., Lu, B., Chen, L., Hu, L., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.077134 · Cited by 1
“However, all research reports about CD36 in platelets suggest that it enhances platelet function 24,25,28 unless CD36 is degraded.”
Maiorca, F., Sabetta, A., Sangineto, M., Pallucci, D., Dufies, O., Poli, V., Gioia, M. D., D’Amico, T., Miglionico, M., Lombardi, L., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.126.325001 · Cited by 1
Thrombosis, Atherosclerosis and Atherothrombosis – New Insights and Experimental Protocols
Dimitrova‐Shumkovska, J., Veenman, L., Roim, I., Leschiner, S., & Gavish, M. (2015) · InTech eBooks · doi:10.5772/61971 · Cited by 3
“Experimental studies demonstrated a marked reduction of thrombus formation in animals with the deletion of ox-LDL receptor CD36 from platelets [13].”
BackgroundHitsumoto, T. (2017) · Journal of Endocrinology and Metabolism · doi:10.14740/jem448w · Cited by 1
Momi, S., Guglielmini, G., Taranta, G. C., Giglio, E., Monopoli, A., & Gresele, P. (2022) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2022.19 · Cited by 1
The Functional Role of CD36 Involved in Fatty Acid Transduction
Xu, H. (2014) · Digital Commons - USU (Utah State University) · doi:10.26076/cb65-ddf2 · Cited by 2
CD36: An Inflammatory Mediator in Acute Brain Injury
Cho, S., & Febbraio, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8915-3_18 · Cited by 2
Self-citationFree Radicals, Oxidative Stress, and Cardiovascular Disease
Bruckdorfer, K. R. (2011) · Springer eBooks · doi:10.1007/978-0-85729-920-8_7 · Cited by 1
Somuncu, M. U., Demir, A. R., Karakurt, H., Serbest, N. G., Kalaycı, B., Bulut, Ü., & Karakurt, S. T. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618780352 · Cited by 1
“may cause AR.(29) It has also been found that there may be a decrease in the resistance to aspirin with statin therapy.”
BackgroundHaemostatic functions and metabolic profile of subclinical hypothyroid and hypothyroid patients.
Mahajan, A. S., Mahaur, R., Singh, T., Jain, A. K., Dhanwal, D., & Gupta, M. K. (2018) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v17i4.38312 · Cited by 2
Scavenger receptors: targets for antiplatelet therapies?
Gawaz, M. (2008) · Blood · doi:10.1182/blood-2007-12-126185 · Cited by 1
Humoral response towards high density lipoprotein : a new mechanism for atherogenesis
Batuca, J. R. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Thrombosis in Diabetes and Its Clinical Management
Ajjan, R., & Grant, P. J. (2014) · Wiley eBooks · doi:10.1002/9781118337967.ch8
AUTOIMMUNE RESPONSES TO ATHEROSCLEROTIC
Wu, H. (2011)
Platelets in atherothrombosis : roles of CD36 and P2Y12 receptors
Nergiz‐Unal, R. (2011) · Research Publications (Maastricht University) · doi:10.26481/dis.20110623ru
Liquid chromatography - Mass spectrometry for the study of arachidonic acid metabolites
Liu, X. (2012) · ScholarlyCommons (University of Pennsylvania)
Platelet function under systemic oxidative stress
Assinger, A. (2008) · University of Vienna · doi:10.25365/thesis.3331
Colas, R. A., Lagarde, M., & Calzada, C. (2010) · OpenGrey (Institut de l'Information Scientifique et Technique)
Pathophysiology of the prothrombotic state in metabolic syndrome
González, I. P., Moore‐Carrasco, R., Marcelo Alarcón, L., Armando Rojas, R., Escudero, V., & Sandra Hasbún, A. (2009)
Molecule Links Dyslipidemia, Oxidative Stress, and Thrombosis
Komaroff, A. L. (2007) · Journal watch · doi:10.1056/jw200709250000007
Charakterisierung von CXCL16/SR-PSOX als neuer Scavenger-Rezeptor auf Thrombozyten
Direktor, Ä., & Gawaz, M. (2013)
PTU Induction Provide Quick Screening of Hypo and Hyperlipidemia
Attitalla, I. H. (2011) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2011.1132.1133
Role of CD36 in Platelet Function
Arunima, G. (2007) · OhioLink ETD Center (Ohio Library and Information Network)
Wu, H. (2011) · Digital Commons-TMC (Texas Medical Center)
The mechanisms of carboxyalkylpyrrole induced angiogenesis
West, X. Z. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Platelet activation in trauma and other inflammatory conditions
Montague, S. J. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Hitsumoto, T. (2017) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000021
“Several mechanisms, via oxidative stress, cause impairment of blood rheology, such as platelet aggregation and elevation of plasma viscosity [25,26].”
BackgroundApolipoprotein A-IV: Novel αIIbβ3 Integrin Ligand and Endogenous Thrombotic Inhibitor
Xu, X. (2015) · TSpace (University of Toronto)
Jobela, B. C. (2019) · UpSpace Institutional Repository (University of Pretoria)
Risk stratification for thrombosis in type 2 diabetic patients
Daniels, S. (2026) · e-space (Manchester Metropolitan University) · doi:10.83056/mmu.32479518
Novel aspects of blood platelet function and biology measured by fluorescent flow cytometry
Hindle, M. S. (2019) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Zhang, X., Gu, Y. H., Deng, H., Xu, Z. Q., Zhong, Z., Jin, H. M., & Yang, X. H. (2020) · Research Square · doi:10.21203/rs.3.rs-70758/v3
The Role of Liver X Receptors in Reverse Cholesterol Transport and Atherosclerosis
Breevoort, S. R. (2014) · doi:10.18130/v3925p
Du, X., & Estevez, B. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717960720.793463579
Platelets in the Pathogenesis of Vascular Disease and Their Role as a Therapeutic Target
McFadyen, J. D., & Peter, K. (2020) · Springer eBooks · doi:10.1007/978-3-030-43683-4_11
Zhang, X., Deng, H., Xu, Z. Q., Zhong, Z., Jin, H. M., & Yang, X. H. (2020) · Research Square · doi:10.21203/rs.3.rs-70758/v1
Silverstein, R. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00144-x
Self-citationZhang, X., Deng, H., Xu, Z. Q., Zhong, Z., Jin, H. M., & Yang, X. H. (2020) · Research Square · doi:10.21203/rs.3.rs-70758/v2
Гизатуллин, Р. Х., Лейдерман, И. Н., Мухаметзянов, А. М., & Gizatullin, R. R. (2023) · Russian Biomedical Research · doi:10.56871/rbr.2022.45.27.009
Krott, K. J., Feige, T., Bosbach, A., Krüger, I., Pfeiler, S., Beele, A. N., Reusswig, F., Schickentanz-Dey, E., Chadt, A., Kelm, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.18.585356
Lipoprotein(a): an important consideration for DAPT therapy after PCI
Cui, K., & Dou, K. (2024) · Cardiology Journal · doi:10.5603/cj.98494
Sotoudeheian, M., Azarbad, R., Mirahmadi, S., Pirhayati, M., Moradi, M., & Pazoki–Toroudi, H. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010324744240916110446 · Cited by 1
Wu, Z. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103809
Zotova, I. V., & Cherkasov, A. O. (2024) · Kardiologiia · doi:10.18087/cardio.2024.12.n2843
Guerrero-Carreño, X., Smits, S., Lasso, A. E., Samiotaki, M. K., Navarro, V. C., Iborra, F. J., Rantanen, F., Álvarez‐Larrán, A., Angona, A., Bellosillo, B., et al. (2025) · medRxiv · doi:10.1101/2025.03.10.25323560
An Immune Assay to Quantify the Neutralization of Oxidation-Specific Epitopes by Human Blood Plasma
Jelic, M., Jokesch, P., Oskolkova, O., Faustmann, G., Winklhofer‐Roob, B. M., Ullrich, B., Krauß, J., Übelhart, R., Gesslbauer, B., & Bochkov, V. N. (2025) · Antioxidants · doi:10.3390/antiox14080903 · Cited by 1
Platelet Involvement in Protozoal Diseases
Loughran, N., & Thachil, J. V. (2025) · Springer eBooks · doi:10.1007/978-3-031-96352-0_18
FcR γ-chain and platelet hyperactivity
Silverstein, R. L. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017581
Self-citationPlatelets, Vascular Inflammation, and Atherosclerosis
Gawaz, M. P., Rohlfing, A.-K., & Castor, T. (2025) · Springer eBooks · doi:10.1007/978-3-031-96352-0_6
Kille, A., Kaier, K., Nührenberg, T. G., Franke, K., Valina, C. M., Yang, X., Leibundgut, G., Neumann, F., Westermann, D., Hochholzer, W., et al. (2026) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03210-2
Cai, Y., Wei, M., Gu, Y., Wang, L., & Li, X. (2026) · BMC Neurology · doi:10.1186/s12883-026-04681-3
“These oxidized lipoproteins have the potential to activate platelets [11, 12].”
Atherogenic apolipoprotein C-III may not be as bad as we thought
Smith, A. N., Zhang, Z., & Zheng, Z. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.02.023
Time-Critical Cardiovascular Risk After COVID-19: A Population-Based Analysis Across Variant Eras
Howick, J., V, Gersh, B., Scott, C., Chamberlain, A., Shapiro, B., McLeod, C., Niekerk, C. V. V., Taylor, B., Fairweather, D., Sanchez, C. V., et al. (2026) · Mayo Clinic Proceedings: Innovations, Quality & Outcomes · doi:10.1016/j.mayocpiqo.2026.100721
Metadata
- Authors
- Podrez, E. A., Byzova, T. V., Febbraio, M., Salomon, R. G., Ma, Y., Valiyaveettil, M., Poliakov, E., Sun, M., Finton, P. J., Curtis, B. R., Chen, J., Zhang, R., Silverstein, R. L., & Hazen, S. L.
- Affiliations
- Cleveland Clinic (US)
- Case Western Reserve University (US)
- Versiti Blood Center of Wisconsin (US)
- Corresponding author
- Podrez, Eugene A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-08-26
- Volume
- 13
- Issue
- 9
- Pages
- 1086-1095
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC3042888
- OpenAlex
- W2029684068
- Cited by
- 513
- References
- 47
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 18 · 2023: 29 · 2022: 32 · 2021: 27 · 2020: 27 · 2019: 25 · 2018: 23 · 2017: 24 · 2016: 16 · 2015: 27 · 2014: 26 · 2013: 28 · 2012: 36
- FWCI
- 19.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL071625., P01HL046403, HL053315, HL 073311, HL076491, HL-072942, R01HL070083, P50 HL-81011, HL077107, HL077213, P01HL072942, P50HL077107, P01HL077107, R01HL077213, P01HL076491, HL 70621, HL70083, R01HL053315, HL-46403, P01HL073311, R01HL070621, P50HL081011, R01HL071625)
- National Center for Research Resources (M01RR018390)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- hyperlipidemia, oxidative stress, prothrombotic phenotype, oxidized lipids, platelet activation, scavenger receptors, dyslipidemia, thrombosis, HDL cholesterol
- MeSH terms
- Animals, Blood Platelets, Humans, Hyperlipidemias, Male, Phenotype, Phospholipids, Prothrombin, Thrombosis, Platelet Activation, Antigens, CD, Gene Deletion, Mice, Knockout, Oxidative Stress, CD36 Antigens, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.